摘要
目的:探讨结外NK/T细胞淋巴瘤(鼻型)(ENKTCL)可能的预后因素。方法:回顾性分析31例ENKTCL患者的临床资料,对临床特点、可能的预后相关实验室指标及治疗模式行预后单因素分析。结果:治疗前ECOG体能状态评分0~1的患者占94%,Ann ArborⅠ/Ⅱ期患者占42%,国际预后指数低危患者占39%,低蛋白血症患者占29%。近期疗效完全缓解率48%(13/27例),中位生存时间28个月。1年、2年和3年的总生存率分别为78%、59%和48%。单因素分析显示治疗前白蛋白水平、治疗模式及近期疗效与ENKTCL患者的预后有关。结论:治疗前白蛋白水平、治疗模式及近期疗效可作为ENKTCL预后的参考因素。
Objective:To investigate the prognostic factors of extranodal NK/T-cell lymphoma,nasal type(ENKTCL).Method:Records of 31 patients with pathologically confirmed ENKTCL,treated from Aug.1999 to Jul.2008,were reviewed.Detailed clinical and laboratory data and therapeutic modality were included in univariate analysis.Result:Of the 31 patients,42% of the patients were in Ann Arbor Ⅰ/Ⅱ stage.International prognostic index(IPI)in 39% patients were low risk.ECOG performance status(PS)scores in 94% patients were 0-1.And 65% patients presented B symptoms.With a median follow-up duration of 12 months,the median overall survival time was 28 months.The 1,2 and 3 year overall survival(OS)rates were 78%,59%,48%.In univariate analysis,the level of albumin(ALB),therapeutic modality and short-term response were prognostic factors of ENKTCL.Conclusion:The level of ALB,therapeutic modality and short-term response may be prognostic factors of ENKTCL.
出处
《临床血液学杂志》
CAS
2010年第4期391-393,397,共4页
Journal of Clinical Hematology
关键词
结外NK/T细胞淋巴瘤
预后
白蛋白
治疗模式
近期疗效
extranodal NK/T-cell lymphoma
nasal type
prognosis
albumin
therapeutic modality
short-term response